Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles - PubMed (original) (raw)
Clinical Trial
Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles
Liam O'Mahony et al. Gastroenterology. 2005 Mar.
Abstract
Background & aims: The aim of this study was to compare the response of symptoms and cytokine ratios in irritable bowel syndrome (IBS) with ingestion of probiotic preparations containing a lactobacillus or bifidobacterium strain.
Methods: Seventy-seven subjects with IBS were randomized to receive either Lactobacillus salivarius UCC4331 or Bifidobacterium infantis 35624, each in a dose of 1 x 10 10 live bacterial cells in a malted milk drink, or the malted milk drink alone as placebo for 8 weeks. The cardinal symptoms of IBS were recorded on a daily basis and assessed each week. Quality of life assessment, stool microbiologic studies, and blood sampling for estimation of peripheral blood mononuclear cell release of the cytokines interleukin (IL)-10 and IL-12 were performed at the beginning and at the end of the treatment phase.
Results: For all symptoms, with the exception of bowel movement frequency and consistency, those randomized to B infantis 35624 experienced a greater reduction in symptom scores; composite and individual scores for abdominal pain/discomfort, bloating/distention, and bowel movement difficulty were significantly lower than for placebo for those randomized to B infantis 35624 for most weeks of the treatment phase. At baseline, patients with IBS demonstrated an abnormal IL-10/IL-12 ratio, indicative of a proinflammatory, Th-1 state. This ratio was normalized by B infantis 35624 feeding alone.
Conclusions: B infantis 35624 alleviates symptoms in IBS; this symptomatic response was associated with normalization of the ratio of an anti-inflammatory to a proinflammatory cytokine, suggesting an immune-modulating role for this organism, in this disorder.
Comment in
- Probiotics: an ideal anti-inflammatory treatment for IBS?
Spiller R. Spiller R. Gastroenterology. 2005 Mar;128(3):783-5. doi: 10.1053/j.gastro.2005.01.018. Gastroenterology. 2005. PMID: 15765414 Review. No abstract available. - Is Bifidobacterium a more effective probiotic therapy than Lactobacillus for patients with irritable bowel syndrome?
Furrie E. Furrie E. Nat Clin Pract Gastroenterol Hepatol. 2005 Jul;2(7):304-5. doi: 10.1038/ncpgasthep0219. Nat Clin Pract Gastroenterol Hepatol. 2005. PMID: 16265282 No abstract available.
Similar articles
- The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial.
Ki Cha B, Mun Jung S, Hwan Choi C, Song ID, Woong Lee H, Joon Kim H, Hyuk J, Kyung Chang S, Kim K, Chung WS, Seo JG. Ki Cha B, et al. J Clin Gastroenterol. 2012 Mar;46(3):220-7. doi: 10.1097/MCG.0b013e31823712b1. J Clin Gastroenterol. 2012. PMID: 22157240 Clinical Trial. - Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome.
Whorwell PJ, Altringer L, Morel J, Bond Y, Charbonneau D, O'Mahony L, Kiely B, Shanahan F, Quigley EM. Whorwell PJ, et al. Am J Gastroenterol. 2006 Jul;101(7):1581-90. doi: 10.1111/j.1572-0241.2006.00734.x. Am J Gastroenterol. 2006. PMID: 16863564 Clinical Trial. - Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis.
Yuan F, Ni H, Asche CV, Kim M, Walayat S, Ren J. Yuan F, et al. Curr Med Res Opin. 2017 Jul;33(7):1191-1197. doi: 10.1080/03007995.2017.1292230. Epub 2017 Mar 7. Curr Med Res Opin. 2017. PMID: 28166427 Review. - A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome.
Drouault-Holowacz S, Bieuvelet S, Burckel A, Cazaubiel M, Dray X, Marteau P. Drouault-Holowacz S, et al. Gastroenterol Clin Biol. 2008 Feb;32(2):147-52. doi: 10.1016/j.gcb.2007.06.001. Epub 2008 Mar 4. Gastroenterol Clin Biol. 2008. PMID: 18387426 Clinical Trial. - The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review.
Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS. Brenner DM, et al. Am J Gastroenterol. 2009 Apr;104(4):1033-49; quiz 1050. doi: 10.1038/ajg.2009.25. Epub 2009 Mar 10. Am J Gastroenterol. 2009. PMID: 19277023 Review.
Cited by
- Taeniasis impacts human gut microbiome composition and function.
Mu W, Ma P, Wang Y, Li Y, Ding Y, Zou Y, Pu L, Yan Q, Kong H, Guo X, Guo A, Li H, Wang S. Mu W, et al. ISME J. 2024 Jan 8;18(1):wrae213. doi: 10.1093/ismejo/wrae213. ISME J. 2024. PMID: 39441994 Free PMC article. - Unraveling the relative abundance of psychobiotic bacteria in children with Autism Spectrum Disorder.
Darwesh MK, Bakr W, Omar TEI, El-Kholy MA, Azzam NF. Darwesh MK, et al. Sci Rep. 2024 Oct 17;14(1):24321. doi: 10.1038/s41598-024-72962-3. Sci Rep. 2024. PMID: 39414875 Free PMC article. - The Efficacy of Probiotics Supplementation on the Quality of Life of Patients with Gastrointestinal Disease: A Systematic Review of Clinical Studies.
Moludi J, Saber A, Zozani MA, Moradi S, Azamian Y, Hajiahmadi S, Pasdar Y, Moradi F. Moludi J, et al. Prev Nutr Food Sci. 2024 Sep 30;29(3):237-255. doi: 10.3746/pnf.2024.29.3.237. Prev Nutr Food Sci. 2024. PMID: 39371511 Free PMC article. Review. - Analysis of Gut Bacterial and Fungal Microbiota in Children with Autism Spectrum Disorder and Their Non-Autistic Siblings.
Retuerto M, Al-Shakhshir H, Herrada J, McCormick TS, Ghannoum MA. Retuerto M, et al. Nutrients. 2024 Sep 5;16(17):3004. doi: 10.3390/nu16173004. Nutrients. 2024. PMID: 39275319 Free PMC article. - Probiotics and Fecal Microbiota Transplantation in Major Depression: Doxa or Episteme?
Evrensel A. Evrensel A. Adv Exp Med Biol. 2024;1456:67-83. doi: 10.1007/978-981-97-4402-2_4. Adv Exp Med Biol. 2024. PMID: 39261424 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources